Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone585-271-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$720,000.00
Profitability
Miscellaneous
Employees44
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Vaccinex (NASDAQ:VCNX) Frequently Asked Questions
What is Vaccinex's stock symbol?
Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."
How were Vaccinex's earnings last quarter?
Vaccinex Inc (NASDAQ:VCNX) announced its earnings results on Wednesday, August, 14th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.07. The company had revenue of $0.03 million for the quarter. Vaccinex had a negative net margin of 6,349.13% and a negative return on equity of 306.27%. View Vaccinex's Earnings History.
When is Vaccinex's next earnings date?
What price target have analysts set for VCNX?
3 analysts have issued 1-year price objectives for Vaccinex's stock. Their predictions range from $22.00 to $22.00. On average, they expect Vaccinex's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 340.9% from the stock's current price. View Analyst Price Targets for Vaccinex.
What is the consensus analysts' recommendation for Vaccinex?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaccinex.
Has Vaccinex been receiving favorable news coverage?
Media stories about VCNX stock have been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaccinex earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Vaccinex.
Are investors shorting Vaccinex?
Vaccinex saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 22,300 shares, an increase of 23.9% from the June 30th total of 18,000 shares. Based on an average trading volume of 8,100 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.0% of the company's stock are sold short. View Vaccinex's Current Options Chain.
Who are some of Vaccinex's key competitors?
Some companies that are related to Vaccinex include Clovis Oncology (CLVS), Albireo Pharma (ALBO), CannTrust (CTST), Kalvista Pharmaceuticals (KALV), NuCana (NCNA), Kindred Biosciences (KIN), Syndax Pharmaceuticals (SNDX), Protagonist Therapeutics (PTGX), Geron (GERN), Lannett (LCI), Dynavax Technologies (DVAX), Minerva Neurosciences (NERV), DURECT (DRRX), OptiNose (OPTN) and Flex Pharma (FLKS).
What other stocks do shareholders of Vaccinex own?
Who are Vaccinex's key executives?
Vaccinex's management team includes the folowing people:
- Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)
- Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
- Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
- Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
- Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)
When did Vaccinex IPO?
(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
Who are Vaccinex's major shareholders?
Vaccinex's stock is owned by many different of institutional and retail investors. Top institutional investors include Oppenheimer & Co. Inc. (0.14%) and Creative Planning (0.09%). Company insiders that own Vaccinex stock include Albert Friedberg, Maurice Zauderer and Scott E Royer. View Institutional Ownership Trends for Vaccinex.
Which major investors are buying Vaccinex stock?
VCNX stock was purchased by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc. and Creative Planning. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Maurice Zauderer and Scott E Royer. View Insider Buying and Selling for Vaccinex.
How do I buy shares of Vaccinex?
Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vaccinex's stock price today?
One share of VCNX stock can currently be purchased for approximately $4.99.
How big of a company is Vaccinex?
Vaccinex has a market capitalization of $74.15 million and generates $720,000.00 in revenue each year. The company earns $-29,520,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Vaccinex employs 44 workers across the globe.View Additional Information About Vaccinex.
What is Vaccinex's official website?
How can I contact Vaccinex?
Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]
MarketBeat Community Rating for Vaccinex (NASDAQ VCNX)
MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote "Outperform" if you believe VCNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
